Tresiba scores well vs insulin glargine in lowering risk of hypoglycemia and HbA1c

19 September 2019

According to new data from the CONCLUDE head-to-head trial, Tresiba (insulin degludec) showed an overall lower risk of hypoglycemia, also known as a hypo or low blood sugar, at a significantly lower HbA1c, compared with insulin glargine U300 in adults with type 2 diabetes uncontrolled on basal insulin with or without oral anti-diabetic drugs (OADs).

Sales of Tresiba is marketed by Danish diabetes care giant Novo Nordisk (NOV: N) and generated sales of 8 billion Danish kroner ($1.2 billion) for the company last year. The firm’s shares were up 2% in premarket on light volume and still 1.2% higher at 349.85 kroner by early afternoon.

Results from the CONCLUDE trial were presented today at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD 2019) in Barcelona, Spain.1

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK